Research Projects Page

This report discusses reasons anticancer therapies may need to be initiated on admission, challenges of doing so, perspectives and experiences from 3 unique HSSPs on addressing these challenges, and finally, best practice recommendations in managing high cost oral anticancer therapies for admitted patients.

This study evaluated access and affordability of HIV PrEP in patients seen at a multidisciplinary PrEP clinic. In this cohort of mostly commercially insured men, the majority were able to access PrEP with low out-of-pocket costs facilitated by manufacturer assistance. Although generalizability beyond this population is limited, these results contradict perceived financial barriers to PrEP access.

This case series describes the safety and effectiveness outcomes of patietns requiring HCV DAA tablet manipulation. This data along with a comprehensive review of other reports of DAA manipulation demonstrate the safety and efficacy of tablet manipulation.

In this study, we found the time to access pimavanserin reduced by 21 days on average after pharmacist integration. Similarly, the rate of third party approval increased by 16% and treatment initiation increased by 18%.

This study retrospectively reviewed adherence and real-world outcomes of inflammatory bowel disease patients who initiated tofacitinib at a single care center. Sixty-three patients were identified. All patients failed at least on prior biologic therapy. Mean proportion of days covered was 95.7% for ulcerative colitis and 93.1% for Crohn's disease. Significant clinical and endoscopic response was seen. Adherence was high in a cohort with high refractory disease.

The purpose of this article is to describe medication alternatives available for use in patients with certain bleeding disorders during the intranasal desmopressin recall. Intranasal desmopressin plays a key role in treatment of these patients and the recall is expected to impact availability until mid to late 2023. We hope the details of the article can help other institutions select the best treatment alternative for their patients during this time.

This study evaluated adherence rates and health outcomes across three academic centers with integrated specialty pharmacies. Centers with specialty pharmaies had high medicaiton possession ratio (MPR). Self-injectable biologic therapy non-adherence was associated with higher likelihood of emergency department visits and hospitalizations.

This study evaluated patient-reported outcomes (PROs) and pharmacist interventions in patients serviced by VSP in various clinical conditions. In patients with MS specifically, we found that 98% of patients reported no adverse effects, 90% reported no missed doses, and 98% reported their medication worked "good" or "excellent." Pharmacist interventions were commonly related to adherence, safety monitoring, and adverse effects. PROs can be useful to drive meaningful pharmacist interventions.

This study evaluated patient-reported outcomes in neurology specialty disease states gathered via a monthly refill questionnaire. and corresponding pharmacist interventions. There was a high patient-reported adherence rate at 91%. Most pharmacist interventions focused on ensuring safe and effective medication use. Addressing recent healthcare utilization was the most common intervention.

This study evaluates rates and reasons for switching and cycling in patients with RA. The most common reasons for switching and cycling were loss of efficacy, no efficacy and intolerable adverse effects.